The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.
about
Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review[Success for a new generation of disease-modifying antirheumatic drugs : The Janus kinase inhibitor baricitinib in rheumatoid arthritis].The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.Small Molecules in the Treatment of Psoriasis.Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study.Trisomy 21 consistently activates the interferon response.Systemic methotrexate for the treatment of psoriasis.Recommendations for the development and validation of flow cytometry-based receptor occupancy assays.Small molecules as therapy for uveitis: a selected perspective of new and developing agents.Efficacy of baricitinib in the treatment of rheumatoid arthritis.Role of receptor occupancy assays by flow cytometry in drug development.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.A novel therapeutic paradigm for patients with extensive alopecia areata.Baricitinib for the treatment of rheumatoid arthritis.Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential.Baricitinib: First Global Approval.Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib.Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Investigational drugs in systemic vasculitis.Chemical JAK inhibitors for the treatment of rheumatoid arthritis.Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.The role of the JAK/STAT signal pathway in rheumatoid arthritis.Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis
P2860
Q26774874-9AFE1ACA-BE62-4E0E-AAA4-D5C0CDCDE739Q30313219-0FD5634C-099E-458A-863D-208573B73CA0Q33890805-9816612C-63C7-4FAB-923D-03C3151286F2Q35740706-82DE55A2-E20C-489B-9EBD-1A7FD6D51111Q36912333-E767BA34-4940-4EDC-882E-BE09014642BEQ37235217-8D381F4B-7396-49A0-BB14-4F94CFF2B1E7Q38380882-B0E9FD88-A249-4DA4-8E46-8811BC0FD5E5Q38632834-7ACD7DCC-A9F2-4255-BA21-88F2DD99925BQ38650868-E2AEA9B2-5A9E-405C-85A2-47435DD8E5C1Q38652849-68F187BB-9B55-4028-8F01-ABD5737C8860Q38679593-7128BFE6-50B9-4EB4-B7E0-2F46EDFA591CQ38751230-F2336B99-E91A-4E0B-828F-3409EF8028CAQ38821079-A2460ABB-4DEB-434D-A597-59DD11ABE41BQ38831003-78F311D8-6ACD-4ACB-A335-81D75F3D34A4Q38840787-C944996D-0789-4A0D-B315-185EEF9E8768Q38932097-DDFEB9C0-CFCA-4CE6-B929-F3EB9E721099Q39177156-A0C92C65-87A7-4FE7-835E-15E28191B6CDQ40267379-CC8AB4B6-9827-4B61-9FFD-F1BDFC252CECQ46119650-7C7BF2BF-2F5A-4906-B55F-F52C507EEC66Q47103417-D385CC99-BC5F-4DF7-9163-2AEB2768A0EAQ47439880-3397924F-F406-4593-B243-D3502DF0DBE0Q47602482-9797BAB2-898A-47E1-9174-AE3EF8A00BCAQ48556502-4BB69D69-9943-4FD9-8933-9A93DFC067BCQ51834131-A1E534ED-A4C1-4FF9-8C44-FBE3F1E3C19CQ54172510-F28C8B58-A746-40F9-BED3-0A278C37DF00Q54980743-8AE0515A-F43A-4B9E-9595-5C57729367DFQ55487787-E851B32A-AFCA-4500-9C21-F98498A65462Q57330101-2A44CAB1-D12E-4D48-9B0A-BC9078EEB317
P2860
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
The pharmacokinetics, pharmaco ...... ibitor, in healthy volunteers.
@en
The pharmacokinetics, pharmaco ...... ibitor, in healthy volunteers.
@nl
type
label
The pharmacokinetics, pharmaco ...... ibitor, in healthy volunteers.
@en
The pharmacokinetics, pharmaco ...... ibitor, in healthy volunteers.
@nl
prefLabel
The pharmacokinetics, pharmaco ...... ibitor, in healthy volunteers.
@en
The pharmacokinetics, pharmaco ...... ibitor, in healthy volunteers.
@nl
P2093
P2860
P356
P1476
The pharmacokinetics, pharmaco ...... ibitor, in healthy volunteers.
@en
P2093
Jack G Shi
Naresh Punwani
Peggy A Scherle
Swamy Yeleswaram
Thomas Emm
William V Williams
Xuejun Chen
P2860
P304
P356
10.1002/JCPH.354
P577
2014-12-01T00:00:00Z